RA medications require unique cost considerations December 18, 2015 By Tracey Walker When it comes to managing rheumatoid arthritis drugs, cost comes in various sizes and shapes. Evolving research improves lymphoma diagnosis, treatment December 07, 2015 By Bryant Furlow As researchers uncover biomarkers for cancer subtypes, collaboration between researchers, pathologists and physicians will improve accurate diagnosis of lymphoma subtypes. Expert reviews myeloma combo treatments December 07, 2015 By Bryant Furlow Myeloma combination treatments get the once-over by leading cancer expert. FDA approves first immunostimulatory antibody for multiple myeloma December 01, 2015 By Tracey Walker An oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved. First generic MS drug could have big impact June 05, 2015 By Tracey Walker FDA’s approval of the first generic version of Copaxone for treating patients with relapsing forms of multiple sclerosis has industry insiders contemplating the impact on the generics market as well as payer coverage strategies. Adverse tiering to deter costly patients comes under fire June 01, 2015 By Mari Edlin Critics charge that the practice of adverse tiering to deter costly patients is violating the Affordable Care Act's coverage mandate. New model for managing specialty pharmacy aims to improve quality at a reduced cost April 27, 2015 Both public and private purchasers are in an important position to act as catalysts of change in managing specialty pharmacy. Increasing regulations could raise managed drug plan costs April 21, 2015 By Tracey Walker Increasing unnecessary regulations on drug plans could inflict higher costs on the 220 million Americans who get their medications through a managed drug plan, according to a new report.